Global Phase I - IV Clinical Development Services Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report ID: GIR2204180002 | Category: Pharma & Healthcare | Pages: 123 | Format: PDF | Published Date: May 12,2022

Request Sample Enquiry before buying Ask For Discount

Single User-$3480.00 Multi User-$5220.00

Report Description
View Table of Contents

Report Summary

The Phase I - IV Clinical Development Services market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Phase I - IV Clinical Development Services market size is estimated to be worth US$  million in 2021 and is forecast to a readjusted size of USD  million by 2028 with a CAGR of  % during forecast period 2022-2028. Pharmaceutical Companies accounting for  % of the Phase I - IV Clinical Development Services global market in 2021, is projected to value USD  million by 2028, growing at a  % CAGR in next six years. While Early Phase segment is altered to a  % CAGR between 2022 and 2028.
Global key companies of Phase I - IV Clinical Development Services include Syneos Health, PPD, GVI CDS, Parexel, and Clinical Leader, etc. In terms of revenue, the global top four players hold a share over  % in 2021.
Market segmentation
Phase I - IV Clinical Development Services market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
    Early Phase
    Phase II-III
    Phase IIIb-IV
Market segment by Application, can be divided into
    Pharmaceutical Companies
    Medical Device Companies
    Contract Research Organizations
Market segment by players, this report covers
    Syneos Health
    PPD
    GVI CDS
    Parexel
    Clinical Leader
    Thermo Fisher Scientific
    LabCorp
    Worldwide Clinical Trial
    CROS NT
    Dynakin
    Rho, Inc.
    Synteract
    ICBio CRO
    Sofpromed
    Profil
    ICON Plc
    Clinipace
    OCT Clinical
    EPS Group
    Beijing Sun-novo Pharmaceutical Research
    Dmedglobal
    WuXi AppTec
    Elixir Clinical Research
Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Phase I - IV Clinical Development Services product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Phase I - IV Clinical Development Services, with revenue, gross margin and global market share of Phase I - IV Clinical Development Services from 2019 to 2022.
Chapter 3, the Phase I - IV Clinical Development Services competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Phase I - IV Clinical Development Services market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Phase I - IV Clinical Development Services research findings and conclusion, appendix and data source.

1 Market Overview
    1.1 Product Overview and Scope of Phase I - IV Clinical Development Services
    1.2 Classification of Phase I - IV Clinical Development Services by Type
        1.2.1 Overview: Global Phase I - IV Clinical Development Services Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Phase I - IV Clinical Development Services Revenue Market Share by Type in 2021
        1.2.3 Early Phase
        1.2.4 Phase II-III
        1.2.5 Phase IIIb-IV
    1.3 Global Phase I - IV Clinical Development Services Market by Application
        1.3.1 Overview: Global Phase I - IV Clinical Development Services Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Pharmaceutical Companies
        1.3.3 Medical Device Companies
        1.3.4 Contract Research Organizations
    1.4 Global Phase I - IV Clinical Development Services Market Size & Forecast
    1.5 Global Phase I - IV Clinical Development Services Market Size and Forecast by Region
        1.5.1 Global Phase I - IV Clinical Development Services Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Phase I - IV Clinical Development Services Market Size by Region, (2017-2022)
        1.5.3 North America Phase I - IV Clinical Development Services Market Size and Prospect (2017-2028)
        1.5.4 Europe Phase I - IV Clinical Development Services Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Phase I - IV Clinical Development Services Market Size and Prospect (2017-2028)
        1.5.6 South America Phase I - IV Clinical Development Services Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Phase I - IV Clinical Development Services Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Phase I - IV Clinical Development Services Market Drivers
        1.6.2 Phase I - IV Clinical Development Services Market Restraints
        1.6.3 Phase I - IV Clinical Development Services Trends Analysis
2 Company Profiles
    2.1 Syneos Health
        2.1.1 Syneos Health Details
        2.1.2 Syneos Health Major Business
        2.1.3 Syneos Health Phase I - IV Clinical Development Services Product and Solutions
        2.1.4 Syneos Health Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 Syneos Health Recent Developments and Future Plans
    2.2 PPD
        2.2.1 PPD Details
        2.2.2 PPD Major Business
        2.2.3 PPD Phase I - IV Clinical Development Services Product and Solutions
        2.2.4 PPD Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 PPD Recent Developments and Future Plans
    2.3 GVI CDS
        2.3.1 GVI CDS Details
        2.3.2 GVI CDS Major Business
        2.3.3 GVI CDS Phase I - IV Clinical Development Services Product and Solutions
        2.3.4 GVI CDS Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 GVI CDS Recent Developments and Future Plans
    2.4 Parexel
        2.4.1 Parexel Details
        2.4.2 Parexel Major Business
        2.4.3 Parexel Phase I - IV Clinical Development Services Product and Solutions
        2.4.4 Parexel Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Parexel Recent Developments and Future Plans
    2.5 Clinical Leader
        2.5.1 Clinical Leader Details
        2.5.2 Clinical Leader Major Business
        2.5.3 Clinical Leader Phase I - IV Clinical Development Services Product and Solutions
        2.5.4 Clinical Leader Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Clinical Leader Recent Developments and Future Plans
    2.6 Thermo Fisher Scientific
        2.6.1 Thermo Fisher Scientific Details
        2.6.2 Thermo Fisher Scientific Major Business
        2.6.3 Thermo Fisher Scientific Phase I - IV Clinical Development Services Product and Solutions
        2.6.4 Thermo Fisher Scientific Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Thermo Fisher Scientific Recent Developments and Future Plans
    2.7 LabCorp
        2.7.1 LabCorp Details
        2.7.2 LabCorp Major Business
        2.7.3 LabCorp Phase I - IV Clinical Development Services Product and Solutions
        2.7.4 LabCorp Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 LabCorp Recent Developments and Future Plans
    2.8 Worldwide Clinical Trial
        2.8.1 Worldwide Clinical Trial Details
        2.8.2 Worldwide Clinical Trial Major Business
        2.8.3 Worldwide Clinical Trial Phase I - IV Clinical Development Services Product and Solutions
        2.8.4 Worldwide Clinical Trial Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Worldwide Clinical Trial Recent Developments and Future Plans
    2.9 CROS NT
        2.9.1 CROS NT Details
        2.9.2 CROS NT Major Business
        2.9.3 CROS NT Phase I - IV Clinical Development Services Product and Solutions
        2.9.4 CROS NT Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 CROS NT Recent Developments and Future Plans
    2.10 Dynakin 
        2.10.1 Dynakin Details
        2.10.2 Dynakin Major Business
        2.10.3 Dynakin Phase I - IV Clinical Development Services Product and Solutions
        2.10.4 Dynakin Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 Dynakin Recent Developments and Future Plans
    2.11 Rho, Inc.
        2.11.1 Rho, Inc. Details
        2.11.2 Rho, Inc. Major Business
        2.11.3 Rho, Inc. Phase I - IV Clinical Development Services Product and Solutions
        2.11.4 Rho, Inc. Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.11.5 Rho, Inc. Recent Developments and Future Plans
    2.12 Synteract
        2.12.1 Synteract Details
        2.12.2 Synteract Major Business
        2.12.3 Synteract Phase I - IV Clinical Development Services Product and Solutions
        2.12.4 Synteract Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.12.5 Synteract Recent Developments and Future Plans
    2.13 ICBio CRO
        2.13.1 ICBio CRO Details
        2.13.2 ICBio CRO Major Business
        2.13.3 ICBio CRO Phase I - IV Clinical Development Services Product and Solutions
        2.13.4 ICBio CRO Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.13.5 ICBio CRO Recent Developments and Future Plans
    2.14 Sofpromed
        2.14.1 Sofpromed Details
        2.14.2 Sofpromed Major Business
        2.14.3 Sofpromed Phase I - IV Clinical Development Services Product and Solutions
        2.14.4 Sofpromed Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.14.5 Sofpromed Recent Developments and Future Plans
    2.15 Profil
        2.15.1 Profil Details
        2.15.2 Profil Major Business
        2.15.3 Profil Phase I - IV Clinical Development Services Product and Solutions
        2.15.4 Profil Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.15.5 Profil Recent Developments and Future Plans
    2.16 ICON Plc
        2.16.1 ICON Plc Details
        2.16.2 ICON Plc Major Business
        2.16.3 ICON Plc Phase I - IV Clinical Development Services Product and Solutions
        2.16.4 ICON Plc Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.16.5 ICON Plc Recent Developments and Future Plans
    2.17 Clinipace
        2.17.1 Clinipace Details
        2.17.2 Clinipace Major Business
        2.17.3 Clinipace Phase I - IV Clinical Development Services Product and Solutions
        2.17.4 Clinipace Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.17.5 Clinipace Recent Developments and Future Plans
    2.18 OCT Clinical
        2.18.1 OCT Clinical Details
        2.18.2 OCT Clinical Major Business
        2.18.3 OCT Clinical Phase I - IV Clinical Development Services Product and Solutions
        2.18.4 OCT Clinical Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.18.5 OCT Clinical Recent Developments and Future Plans
    2.19 EPS Group
        2.19.1 EPS Group Details
        2.19.2 EPS Group Major Business
        2.19.3 EPS Group Phase I - IV Clinical Development Services Product and Solutions
        2.19.4 EPS Group Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.19.5 EPS Group Recent Developments and Future Plans
    2.20 Beijing Sun-novo Pharmaceutical Research
        2.20.1 Beijing Sun-novo Pharmaceutical Research Details
        2.20.2 Beijing Sun-novo Pharmaceutical Research Major Business
        2.20.3 Beijing Sun-novo Pharmaceutical Research Phase I - IV Clinical Development Services Product and Solutions
        2.20.4 Beijing Sun-novo Pharmaceutical Research Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.20.5 Beijing Sun-novo Pharmaceutical Research Recent Developments and Future Plans
    2.21 Dmedglobal
        2.21.1 Dmedglobal Details
        2.21.2 Dmedglobal Major Business
        2.21.3 Dmedglobal Phase I - IV Clinical Development Services Product and Solutions
        2.21.4 Dmedglobal Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.21.5 Dmedglobal Recent Developments and Future Plans
    2.22 WuXi AppTec
        2.22.1 WuXi AppTec Details
        2.22.2 WuXi AppTec Major Business
        2.22.3 WuXi AppTec Phase I - IV Clinical Development Services Product and Solutions
        2.22.4 WuXi AppTec Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.22.5 WuXi AppTec Recent Developments and Future Plans
    2.23 Elixir Clinical Research
        2.23.1 Elixir Clinical Research Details
        2.23.2 Elixir Clinical Research Major Business
        2.23.3 Elixir Clinical Research Phase I - IV Clinical Development Services Product and Solutions
        2.23.4 Elixir Clinical Research Phase I - IV Clinical Development Services Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.23.5 Elixir Clinical Research Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global Phase I - IV Clinical Development Services Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Phase I - IV Clinical Development Services Players Market Share in 2021
        3.2.2 Top 10 Phase I - IV Clinical Development Services Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Phase I - IV Clinical Development Services Players Head Office, Products and Services Provided
    3.4 Phase I - IV Clinical Development Services Mergers & Acquisitions
    3.5 Phase I - IV Clinical Development Services New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Global Phase I - IV Clinical Development Services Revenue and Market Share by Type (2017-2022)
    4.2 Global Phase I - IV Clinical Development Services Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
    5.1 Global Phase I - IV Clinical Development Services Revenue Market Share by Application (2017-2022)
    5.2 Global Phase I - IV Clinical Development Services Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
    6.1 North America Phase I - IV Clinical Development Services Revenue by Type (2017-2028)
    6.2 North America Phase I - IV Clinical Development Services Revenue by Application (2017-2028)
    6.3 North America Phase I - IV Clinical Development Services Market Size by Country
        6.3.1 North America Phase I - IV Clinical Development Services Revenue by Country (2017-2028)
        6.3.2 United States Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        6.3.3 Canada Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        6.3.4 Mexico Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
    7.1 Europe Phase I - IV Clinical Development Services Revenue by Type (2017-2028)
    7.2 Europe Phase I - IV Clinical Development Services Revenue by Application (2017-2028)
    7.3 Europe Phase I - IV Clinical Development Services Market Size by Country
        7.3.1 Europe Phase I - IV Clinical Development Services Revenue by Country (2017-2028)
        7.3.2 Germany Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        7.3.3 France Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        7.3.5 Russia Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        7.3.6 Italy Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Phase I - IV Clinical Development Services Revenue by Type (2017-2028)
    8.2 Asia-Pacific Phase I - IV Clinical Development Services Revenue by Application (2017-2028)
    8.3 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Region
        8.3.1 Asia-Pacific Phase I - IV Clinical Development Services Revenue by Region (2017-2028)
        8.3.2 China Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        8.3.3 Japan Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        8.3.4 South Korea Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        8.3.5 India Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        8.3.7 Australia Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
    9.1 South America Phase I - IV Clinical Development Services Revenue by Type (2017-2028)
    9.2 South America Phase I - IV Clinical Development Services Revenue by Application (2017-2028)
    9.3 South America Phase I - IV Clinical Development Services Market Size by Country
        9.3.1 South America Phase I - IV Clinical Development Services Revenue by Country (2017-2028)
        9.3.2 Brazil Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        9.3.3 Argentina Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Phase I - IV Clinical Development Services Revenue by Type (2017-2028)
    10.2 Middle East & Africa Phase I - IV Clinical Development Services Revenue by Application (2017-2028)
    10.3 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Country
        10.3.1 Middle East & Africa Phase I - IV Clinical Development Services Revenue by Country (2017-2028)
        10.3.2 Turkey Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
        10.3.4 UAE Phase I - IV Clinical Development Services Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global Phase I - IV Clinical Development Services Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?